



**Commitment To Patients And Their Families To Develop Therapies In
Critical Care Medicine**

**Conducting Bio-medical Research To Discover And Develop
Novel Therapies**

History

Pharmazz Inc., was founded in 2010 as an Illinois Corporation and in 2017 became a Delaware Corporation. It has following subsidiaries: Pharmazz India Private Limited, Pharmazz UK Limited and Pharmazz Europe Limited.

Company has license agreements with Midwestern University and University of Illinois (USA) and has established strategic collaboration with All India Institute of Medical Sciences (Raipur), National Institute of Pharmaceutical Education and Research (Mohali) and Delhi Pharmaceutical Sciences and Research University (India).

Pharmazz is engaged in developing and commercializing products for critical care medicine.

Pharmazz has launched Lyfaquin® a frontline, life-saving product for hypovolemic shock.

Pharmazz Possesses a World-Class Team that is Highly Motivated and Focused in its Efforts



Board of Directors



Anil Gulati

MD, PhD - Founder & Director, Chairman & CEO

Dr. Gulati is leading clinical development and commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock. He has 54 issued patents. He is Professor Emeritus at Midwestern University and is recipient of Paul R Dawson Biotechnology Award 2014 and Littlejohn Award 2014. Dr. Gulati is a United States Fulbright Scholar 2008-2009 and winner of International Ranbaxy Research Award 2007. Dr. Gulati was the Scientific Reviewer, United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017.



James Ford McDonnell
Director

Dr. McDonnell Received His Undergraduate Degree From Georgetown University And His MD In 1985 From Northwestern University Medical School. Dr. McDonnell Has Also Received Postgraduate Training In Emergency And Internal Medicine At Northwestern University. He Has Made Significant Contributions To The Growth Of Pharmaz . He Is Currently Vice Chair, Professor, Department Of Ophthalmology At Loyola University And Strabismus At Loyola University Medical Center And Director, Retinopathy Of Prematurity Of Neonatal Intensive Care. Dr. Mc Donnell Is The Past President Of The Chicago Ophthalmological Society, And Currently Serves On The Board Of Director Of The Illions Association Of Eye Physician And Surgeons (ISEPS)



Sunil Gulati
MA, MBA - Chief Operating Officer

Mr. Gulati has more than 38 years of experience and knowledge in starting and running medium sized organizations. He is the founding member of Pharmaz India Private Limited and is managing and operating the company since its inception. He was instrumental in initiating and developing a team to conduct all the clinical trials in-house and is extensively involved in selection of sites, the budgetary aspects and legal contracts. Mr. Gulati has provided his expertise to be in full compliance with all related regulatory affairs pertaining to drug development, customs, licensing, FEMA and others. Mr. Gulati has an exceptional ability to create healthy environment for employees.



Lov Verma
IAS (Retd.) - Director

Formerly, Union Health Secretary, Government Of India. Mr. Verma Is A Very Senior Administrator With Deep Experience In The Health Sector. He Was Instrumental In Formulating And Implementing Many Policies Related To The Drug Development Process In India. He Also Has Remarkable Interest In Literary Work.

Management



Anil Gulati
MD, PhD - Founder & Director, Chairman & CEO

Dr. Gulati is leading clinical development and commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock. He has 54 issued patents. He is Professor Emeritus at Midwestern University and is recipient of Paul R Dawson Biotechnology Award 2014 and Littlejohn Award 2014. Dr. Gulati is a United States Fulbright Scholar 2008-2009 and winner of International Ranbaxy Research Award 2007. Dr. Gulati was the Scientific Reviewer, United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017.



David Costello
CPA - Vice President and Controller

Mr. Costello brings about 20 years of accounting, budgeting, audit preparation, reporting and financial modeling experience to Pharmazz. He served as Controller for Julian Toft and Downey, Inc. and as Vice President in Transwestern Commercial Real Estate's Capital Markets Group. Mr. Costello has assisted in the closing of over \$500 million in structured finance and equity transactions. Mr. Costello has a CPA designation, earning the Elijah Watts Sells Award for passing with honors, and graduated from Western Illinois University in finance, Magna Cum Laude.



Sunil Gulati
MA, MBA - Chief Operating Officer

Mr. Gulati has more than 38 years of experience and knowledge in starting and running medium sized organizations. He is the founding member of Pharmazz India Private Limited and is managing and operating the company since its inception. He was instrumental in initiating and developing a team to conduct all the clinical trials in-house and is extensively involved in selection of sites, the budgetary aspects and legal contracts. Mr. Gulati has provided his expertise to be in full compliance with all related regulatory affairs pertaining to drug development, customs, licensing, FEMA and others. Mr. Gulati has an exceptional ability to create healthy environment for employees.



Guru Reddy
MSc, PhD - Executive Vice President

Dr. Reddy has more than 20 years of experience in the biopharmaceutical industry. He has led research and development of products to market success. He managed preclinical development and clinical pharmacology of 4 USFDA approved products. Has a wide range of experience in drug development, including preclinical development, early clinical development, regulatory strategy, intellectual property strategy and technical diligence for licensing. He is an inventor on 17 US patents and has co-authored over 30 peer-reviewed publications.



Vineet Bajaj
Director Accounting & Finance

He is a Certified Public Accountant having more than 30 years of experience in financial planning and analysis. He has performed financial statement audits and SOX internal control review, facilitated external audit review by big ten auditors. He is specialized in financial and accounting systems of the USA and India with emphasis on pharmaceutical sector.



Manish S. Lavhale
M.Pharm, PhD - Director Research & Development

Dr. Lavhale has more than twenty years of experience in pre-clinical and clinical development of novel drugs. He did his PhD in Pharmaceutical Sciences and worked for 4 years as a Post-doctoral Fellow at Midwestern University, USA. At Pharmazz he has played a key role in filing several Investigational New Drug Applications in the USA and India. Dr. Lavhale has broad experience in discovery and development of novel first-in-class drug products in critical care medicine. He is an inventor in several issued patents and has more than 40 publications. He received financial grants from UGC, India and was awarded a grant by the NIH, USA.



Nitesh P. Tiwari
Assistant Medical Director

Dr. Nitesh P. Tiwari received his MD from King Georges Medical University, Lucknow, India. He has more than fifteen years of experience in clinical practice with a specialization in Critical and Surgical Care. He is actively involved in the clinical development of novel pharmacological agents for the last five years. He is leading a team conducting phase II and III clinical trials and in post-marketing clinical studies. Dr. Tiwari joined Pharmazz in 2020 and is leading the clinical development of centhaquine and sovateltide across multiple indications.

Advisors



Birinder S. Marwah

Dr. Birinder S. Marwah is the Chief of Geriatrics at Advocate Illinois Masonic Medical Center in Chicago. He serves as the administrative medical director of Seasons Hospice and Palliative Care in Des Plaines, IL. He is board certified in geriatrics and internal medicine and is a past president to the Indian Medical Associates and prior Chairman of the Indian American Associates Charitable Foundation. He has also served as Convention Chair to the American Association of Physicians of Indian Origin.



Anthony Davenport

He is Professor of Cardiovascular Pharmacology and fellow of St. Catharine's College. He is Director of the human receptor research group, department of Experimental Medicine and Immunotherapeutic in University of Cambridge. He has more than 400 peer reviewed publications.



Matthias Barton

He is professor of Cardiology at University of Zurich, Switzerland. Dr. Barton is a Fellow of the American Heart Association (AHA) and European Society of Cardiology (ESC). He is a member of the working Group on Endothelin and endothelial Factor of the European Society of Hypertension (ESH). Dr. Barton is founder and chairman of the board of directors of the Andreas Gruntzig Foundation and was elected to the Academia Europaea(AE)in 2017.



Shridhar Andurkar

Dr.Andurkar is professor and Chair of Pharmaceutical science at the Midwestern University Chicago college of Pharmacy. He has pursued a program of research involving the design, synthesis, biology evaluation and metabolism of bioactive molecules for the past 17 years. He has been awarded various Distinctions & Honors like Golden Apple Award Teacher of the year, Midwestern University Chicago College of Pharmacy, for many years. He has to his honor one issued patent.



R. C. Simal

Dr. Simal has more than 50 years of leadership, testing and research experience in the pharmaceutical Institutions. He has been the Director of Indian Institute of Toxicology Research, Lucknow. He is member of National Academy of Medical science and has been a Commonwealth Medical Fellow. He has been Consultant to UNIDO, Commonwealth Secretariat and The University of Illinois at Chicago, USA

Focus

Pharmazz has several novel drug products in various clinical stages that are first-in-class with unique mechanisms of action that are different from those of existing therapies.

The company has a pipeline of 12 development programs that include product candidates for hypovolemic shock, septic shock, acute kidney injury, acute cerebral ischemic stroke, Alzheimer's disease, acute spinal cord injury, cardiac arrest, diabetic ketoacidosis, traumatic brain injury, hypoxic-ischemic encephalopathy (HIE).

The company research is focused to develop and commercialize drug products that boost endogenous repair mechanisms.


Patents have been granted in the USA, Europe, China, Canada, Australia, India, and other countries.



Product Pipeline



**Hypovolemic
Shock**



**Septic
Shock**



**Acute
Kidney Injury**



**Cardiac
Arrest**



**Cerebral Ischemic
Stroke**



**Alzheimer's
Disease**



**Acute Spinal
Cord Injury**



**Hypoxic-Ischemic
Encephalopathy**



**Diabetic
Ketoacidosis**



**Opioid
Tolerance**

Status of Products



Products	Pre-Clinical	Clinical			Market
		Phase 1	Phase 2	Phase 3	
Hypovolemic Shock (Centhaquine - Lyfaquin®)	<div></div>				
Septic Shock (Centhaquine)	<div></div>				
Acute Kidney Injury (Centhaquine)	<div></div>				
Cardiac Arrest (Centhaquine)	<div></div>				
Cerebral Ischemic Stroke (Sovateltide)	<div></div>				
Alzheimer's Disease (Sovateltide)	<div></div>				
Acute Spinal Cord Injury (Sovateltide)	<div></div>				
Hypoxic-Ischemic Encephalopathy (Sovateltide)	<div></div>				
Diabetic Ketoacidosis (PMZ-2123)	<div></div>				



Pharmazz Inc.

+1 (630) 780-6087
50 West 75th Street, Suite 105
Willowbrook IL 60527, USA

www.pharmazz.com
info@pharmazz.com

Pharmazz India Pvt. Ltd.

+91 (120) 256-9779
H-6, Site-C, Surajpur, Industrial Area
Greater Noida (UP) – 201307, India